Actinium Pharmaceuticals IncNYSE American:ATNM
- LAST PRICE1.9200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.8000/ 1
- Ask / Lots1.9300/ 28
- Open / Previous Close--- / 1.9200
- Day Range---
- 52 Week Range
- Volume3,179
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATNM |
|---|---|---|
| 09:32 ET | 4105 | 1.85 |
| 09:33 ET | 200 | 1.87 |
| 09:39 ET | 502 | 1.8331 |
| 09:42 ET | 200 | 1.83 |
| 09:44 ET | 3700 | 1.85 |
| 09:46 ET | 1372 | 1.83 |
| 09:50 ET | 600 | 1.83 |
| 09:55 ET | 100 | 1.83 |
| 09:57 ET | 1150 | 1.83 |
| 10:00 ET | 172 | 1.8313 |
| 10:02 ET | 872 | 1.84 |
| 10:04 ET | 680 | 1.83 |
| 10:06 ET | 549 | 1.84 |
| 10:08 ET | 1000 | 1.84 |
| 10:09 ET | 210 | 1.845 |
| 10:11 ET | 598 | 1.85 |
| 10:13 ET | 100 | 1.8593 |
| 10:20 ET | 1037 | 1.85 |
| 10:29 ET | 400 | 1.85 |
| 10:36 ET | 1770 | 1.8505 |
| 10:42 ET | 9280 | 1.88 |
| 10:44 ET | 5000 | 1.874 |
| 10:45 ET | 1300 | 1.875 |
| 10:47 ET | 5500 | 1.8734 |
| 10:49 ET | 500 | 1.875 |
| 10:54 ET | 100 | 1.875 |
| 11:02 ET | 1272 | 1.87 |
| 11:03 ET | 400 | 1.87 |
| 11:09 ET | 534 | 1.87 |
| 11:12 ET | 3100 | 1.8642 |
| 11:16 ET | 1467 | 1.87 |
| 11:21 ET | 440 | 1.875 |
| 11:23 ET | 8898 | 1.9 |
| 11:25 ET | 699 | 1.895 |
| 11:27 ET | 395 | 1.895 |
| 11:32 ET | 1895 | 1.88 |
| 11:34 ET | 1185 | 1.885 |
| 11:38 ET | 3000 | 1.8893 |
| 11:39 ET | 660 | 1.875 |
| 11:43 ET | 436 | 1.8799 |
| 11:48 ET | 300 | 1.8725 |
| 11:57 ET | 3000 | 1.88 |
| 12:03 ET | 7615 | 1.895 |
| 12:06 ET | 395 | 1.89 |
| 12:08 ET | 587 | 1.88 |
| 12:10 ET | 1045 | 1.8991 |
| 12:12 ET | 200 | 1.8911 |
| 12:17 ET | 158 | 1.8993 |
| 12:19 ET | 100 | 1.9 |
| 12:30 ET | 820 | 1.8907 |
| 12:39 ET | 2100 | 1.895 |
| 12:44 ET | 1500 | 1.8905 |
| 12:50 ET | 473 | 1.895 |
| 12:53 ET | 1575 | 1.89 |
| 12:55 ET | 200 | 1.89 |
| 01:00 ET | 100 | 1.89 |
| 01:02 ET | 200 | 1.89 |
| 01:04 ET | 202 | 1.8807 |
| 01:09 ET | 100 | 1.88 |
| 01:20 ET | 710 | 1.88 |
| 01:26 ET | 1678 | 1.9 |
| 01:33 ET | 2000 | 1.89 |
| 01:38 ET | 1070 | 1.89 |
| 01:44 ET | 400 | 1.895 |
| 01:47 ET | 8798 | 1.91 |
| 01:49 ET | 200 | 1.91 |
| 01:56 ET | 102 | 1.9101 |
| 02:00 ET | 2604 | 1.915 |
| 02:02 ET | 700 | 1.91 |
| 02:07 ET | 200 | 1.9187 |
| 02:09 ET | 100 | 1.92 |
| 02:12 ET | 300 | 1.91 |
| 02:16 ET | 685 | 1.9 |
| 02:18 ET | 6385 | 1.9 |
| 02:21 ET | 685 | 1.9 |
| 02:25 ET | 300 | 1.91 |
| 02:27 ET | 100 | 1.905 |
| 02:30 ET | 950 | 1.9 |
| 02:39 ET | 300 | 1.9 |
| 02:41 ET | 200 | 1.9 |
| 02:43 ET | 5165 | 1.9088 |
| 02:45 ET | 100 | 1.91 |
| 02:50 ET | 100 | 1.905 |
| 02:54 ET | 400 | 1.9 |
| 02:56 ET | 3950 | 1.92 |
| 02:59 ET | 200 | 1.915 |
| 03:03 ET | 253 | 1.91 |
| 03:06 ET | 4747 | 1.89 |
| 03:14 ET | 1672 | 1.88 |
| 03:15 ET | 3725 | 1.9 |
| 03:17 ET | 100 | 1.9 |
| 03:19 ET | 100 | 1.9007 |
| 03:21 ET | 100 | 1.9 |
| 03:26 ET | 100 | 1.89 |
| 03:37 ET | 1700 | 1.9 |
| 03:39 ET | 3300 | 1.91 |
| 03:42 ET | 100 | 1.905 |
| 03:48 ET | 660 | 1.91 |
| 03:50 ET | 1738 | 1.92 |
| 03:51 ET | 734 | 1.91 |
| 03:53 ET | 1000 | 1.9 |
| 03:55 ET | 11241 | 1.9 |
| 03:57 ET | 6400 | 1.905 |
| 04:00 ET | 13230 | 1.92 |
Nov 4, 2024
Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm, from 11:02AM ET on Monday Nov 04, 2024 by Dow Jones
11:02AM ET on Monday Nov 04, 2024 by Dow JonesPress Release: Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors, from 7:30AM ET on Monday Nov 04, 2024 by Dow Jones
7:30AM ET on Monday Nov 04, 2024 by Dow JonesActinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors, from 7:30AM ET on Monday Nov 04, 2024 by Dow Jones
7:30AM ET on Monday Nov 04, 2024 by Dow Jones
Nov 3, 2024
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud, from 11:01AM ET on Sunday Nov 03, 2024 by Dow Jones
11:01AM ET on Sunday Nov 03, 2024 by Dow Jones
Nov 2, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Actinium Pharmaceuticals Inc | 59.9M | -1.3x | --- |
Mural Oncology PLC | 60.0M | -0.3x | --- |
Oncolytics Biotech Inc | 82.0M | -3.9x | --- |
enVVeno Medical Corp | 61.6M | -2.6x | --- |
Connect Biopharma Holdings Ltd | 61.9M | -2.9x | --- |
Entera Bio Ltd | 62.5M | -6.5x | --- |
Company Information
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Contact Information
- Headquarters
- 100 Park Ave., 23Rd FloorNEW YORK, NY, United States 10017
- Phone
- 646-677-3870
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- Sandesh Seth
- Chief Financial Officer
- Steve O'Loughlin
- Chief Business Officer
- Lynn Bodarky
- Director
- June Almenoff
- Independent Director
- Jeffrey Chell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $59.9M |
|---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 31.2M |
Actinium Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.15 |
EPS | $-1.52 |
Book Value | $1.32 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 739.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -57,665.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
